[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"n-acetylcysteine\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:n-acetylcysteine":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,55],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":39,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":5},"100611785","phase-2-premedication-with-n-acetylcysteine-and-simethicone-to-improve-mucosal-visualization-in-elective-upper-endoscopy-100611785",false,"NCT07245095","Premedication With N-acetylcysteine and Simethicone to Improve Mucosal Visualization in Elective Upper Endoscopy","Randomized Controlled Trial to Evaluate the Effect of Premedication With N-acetylcysteine and Simethicone on Mucosal Visibility During Elective Upper Gastrointestinal Endoscopy Using the TUGS Score","NACSIMET","Inclusion Criteria:\n\n* Men and women aged 18 to 70 years old.\n* Patients who agree to participate in the clinical trial.\n* Patients without active gastrointestinal bleeding.\n* Signing of informed consent form.\n\nExclusion Criteria:\n\n* Patients with a history of hypersensitivity to N-acetylcysteine\n* Patients with a history of hypersensitivity to simethicone\n* Patients with a previous endoscopic diagnosis\n* Patients with a history of gastric or bariatric surgery\n* Patients with a history of motor disorders (e.g., scleroderma, diabetic gastroparesis)\n* Patients taking medications that delay gastric emptying (GLP-1 analogues)\n* Pregnant or breastfeeding patients\n* Patients who do not agree to participate in the clinical trial",true,"ALL","18 Years","99 Years",{"count":22,"type":23},132,"ESTIMATED","INTERVENTIONAL",[26],"PHASE2","The goal of this randomized, double-blind, placebo-controlled clinical trial is to assess whether the combination of N-acetylcysteine and simethicone improves mucosal visibility during upper gastrointestinal endoscopy in adults aged 18 to 99 years of both sexes, including both healthy individuals and those with non-bleeding gastrointestinal symptoms.\n\nThe main questions this study aims to answer are:\n\nDoes pre-endoscopy administration of N-acetylcysteine\u002Fsimethicone improve mucosal visualization based on the Toronto Upper Gastrointestinal Cleanliness Score (TUGS)?\n\nIs this combination safe and well tolerated in this patient population?\n\nResearchers will compare patients receiving N-acetylcysteine (600 mg) and simethicone (100 mg) orally 20-60 minutes before the procedure with those receiving placebo (water) to determine if there is a significant improvement in TUGS scores.\n\nParticipants will:\n\nReceive a single oral dose of either N-acetylcysteine\u002Fsimethicone or placebo prior to endoscopy\n\nUndergo a routine upper GI endoscopy\n\nHave mucosal cleanliness evaluated using the TUGS scoring system\n\nBe monitored for any adverse events or intolerance",[29,30,31,32,33,34,35,36,37,38],"Esophagogastroduodenoscopy","Simethicone","N-Acetylcysteine","Premedication","Visualization","Esophagogastroduodensocopy (EGD) Procedure","Placebo - Control","Gastritis Associated With Helicobacter Pylori","Tumor Gastric","Lesions in the Esophagus, Stomach, Duodenum or Rectum",[29,40,32,30,41,42],"Mucous Membrane","Acetylcysteine","Gastrointestinal Tract","RECRUITING","2025-11-20",{"date":46,"type":47},"2025-11-24","ACTUAL",{"date":49,"type":47},"2025-09-12",{"date":51,"type":23},"2026-12-31",{"name":53,"class":54},"Hospital General de Mexicali","OTHER",{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":24,"phases":65,"briefSummary":67,"conditions":68,"keywords":77,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":87},"100553318","phase-4-gene-guided-n-acetyl-cysteine-for-prophylaxis-of-anti-tuberculous-drug--induced-hepatitis-100553318","NCT06484530","Gene-guided N-acetyl Cysteine for Prophylaxis of Anti-tuberculous Drug- Induced Hepatitis","Gene-guided N-acetyl Cysteine for Prophylaxis of Anti-tuberculous Drug- Induced Hepatitis: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients aged 18 - 80 years old.\n* Newly diagnosed tuberculosis patients (both pulmonary and extrapulmonary).\n* Received standard anti-tuberculosis medication according to standard regimens (2HRZE\u002F4HR, 2HRE\u002F7HR).\n* Willing to participate in the research\n\nExclusion Criteria:\n\n* Infected with HIV.\n* Severe liver dysfunction classified as Child-Pugh B or C.\n* Chronic untreated liver diseases such as hepatitis B or C, alcoholic liver disease.\n* Abnormal liver function tests including AST \\> 1.5 times the upper limit of normal (48 U\u002FL), ALT \\> 1.5 times the upper limit of normal (55 U\u002FL), ALP \\> upper limit of normal (110 U\u002FL), Total bilirubin \\> upper limit of normal (1.2 mg\u002FdL).\n* Diagnosed with cancer.\n* History of allergy to N-acetylcysteine (NAC).\n* Pregnant or breastfeeding.\n* Severe comorbidities such as CKD stage 4-5, chronic heart failure, severe pulmonary diseases (COPD, bronchiectasis).","80 Years",{"count":64,"type":23},116,[66],"PHASE4","Tuberculosis (TB) remains a significant public health concern in Thailand and globally, especially in tropical regions, with pulmonary TB being predominant. Besides affecting the lungs, TB can also impact extrapulmonary organs. Standard TB treatment involves a combination of drugs administered for at least 6 months, but it can cause adverse effects such as hepatitis. Hepatotoxicity, occurring in 20-60% of patients, is commonly linked to isoniazid, rifampicin, and pyrazinamide. Slow acetylators of the NAT2 gene are particularly susceptible. Previous research suggests N-acetylcysteine (NAC) may mitigate hepatotoxicity, especially among slow acetylators. A recent study by Kittichai Samaithongcharoen and team showed that NAC reduced hepatotoxicity incidence significantly among slow acetylators. This underscores the potential of NAC in preventing drug-induced hepatotoxicity in TB treatment, warranting further investigation against standard treatment protocols.",[69,70,71,72,73,74,75,76,31],"Tuberculosis (TB)","Isoniazid Toxicity","Rifampicin Toxicity","Pyrazinamide Adverse Reaction","Ethambutol Toxicity","NAT2 Slow Acetylator Status","NAT2 Rapid Acetylator Status","NAT2 Polymorphism",[69,70,71,72,73,74,75,76,31],"2024-07-01",{"date":80,"type":47},"2024-07-03",{"date":82,"type":47},"2024-03-12",{"date":84,"type":23},"2024-09-18",{"name":86,"class":54},"Mahidol University",1]